Characterization of BRCA1 and BRCA2 mutations in a large United States sample - Test2 - elhamkhani - TriplyDB

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

http://www.wikidata.org/entity/Q28383993

about

DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers Meta-analysis of BRCA1 and BRCA2 penetrance Chemotherapy of ovarian cancer in elderly patients Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers Tilting at quixotic trait loci (QTL): an evolutionary perspective on genetic causation What are genes "for" or where are traits "from"? What is the question?Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1 Understanding the needs of women considering risk-reducing salpingo-oophorectomy.Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer--a population-based data linkage study.Incorporating medical interventions into carrier probability estimation for genetic counseling.Proteomic approach to breast cancer.Case-control study of fetal microchimerism and breast cancer.Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.Selecting a BRCA risk assessment model for use in a familial cancer clinic.Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes.Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.Breast cancer risk among male BRCA1 and BRCA2 mutation carriers Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience.In their own words: treating very young BRCA1/2 mutation-positive women with care and caution.The BRCA1 variant p.Ser36Tyr abrogates BRCA1 protein function and potentially confers a moderate risk of breast cancer.Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.Breast cancer risks and risk prediction models.Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ A pilot study of knowledge and interest of genetic counseling and testing for hereditary breast and ovarian cancer syndrome among Puerto Rican women.

P2860

Q21144874-CF7ABF56-E0D7-4048-9A74-A7AF66692F07 Q24654786-B5D406B4-2BA6-4CE9-95F1-7D4E1E126582 Q26771397-0A0F23DE-8858-4FAA-8A10-F9431376289A Q26995389-422B9EEA-8A98-4ED6-8435-542CCA25DE21 Q27001043-C602BF73-1A56-489C-A479-DBB972E6AA60 Q28085448-5DA1DEE3-8BD3-4C42-92C5-1A7141D3C6F8 Q28385221-9DBD0343-F05A-4705-9015-C05BC6DA41E1 Q28393055-B5AB09D4-0419-4272-84FF-5542C2475185 Q28539000-F5BBC4E9-D483-48CA-AA87-E4D0BCD4C632 Q30419497-A1909467-7C7A-479C-8E3A-ABA145AEE251 Q30448232-64D40D88-E5DD-4541-AAAE-C29F3937BF48 Q30677729-1DD2F4E9-04DA-48A7-92CC-67B71D23C343 Q33279688-9888EC0C-F2C3-44A9-B401-614B4754E2C8 Q33301436-39CB7687-4E98-40E0-AE06-11BD51A42295 Q33322513-B6B8AFBD-FF77-400D-87C7-A5B95F975E9A Q33338978-69F2CF5D-CB21-442A-B2C7-E486A9CD879B Q33395135-3E295490-7F76-47BA-B143-E0C90BE47DDD Q33416772-7D0D6821-E863-432E-800C-CF354572B5C1 Q33584055-B49BB10D-4F8C-4717-B41B-C08045536EAC Q33792732-A5950079-15D8-464A-B289-81F4CF098498 Q33848119-5C6BA1FD-5BAE-4986-B9A2-F51A1EAD49E2 Q33851843-D65DA530-92CE-4E80-8A18-019B6541F645 Q34154918-996B8929-578F-459D-9A9D-395DE704814E Q34471501-CD81D25E-873F-4B14-BE08-3BD6F4A1AF64 Q34501206-F6BE2E28-3105-42D1-AA9F-45EDCE5798F9 Q34548726-4038F941-C3B9-471C-B35B-97197087D659 Q34613604-DAF45B60-4769-4FC3-8021-F562773DD55A Q34625221-B8F28A94-60C2-41A1-93F4-E3FDCD1F0A48 Q34718829-45C69598-ED66-479A-B4D7-8094A6604EC8 Q34806825-B85D65AA-DE86-44CE-B832-BE2D47B47120 Q34945185-7C60B712-12AC-429B-B558-95E51D1F49D8 Q35019634-BA4475CC-DCD3-4ADE-80F6-CB061B381CAE Q35022825-F6C34842-7F17-4F5B-8C65-945213FA4A10 Q35052323-A0BA0BB2-7049-4BE1-8293-BFBD08C05060 Q35105959-8060A9E4-E320-41CB-A4EA-E5D69E5D8DA1 Q35138569-F1132AFD-CBB8-40D8-9E88-695F189A5928 Q35263848-32C90215-E8D6-426D-B9A8-F565D2D6B637 Q35399596-8070CCE0-38C4-4D8A-BA6D-389400B6321F Q35531714-D3DEBB0D-36EF-415D-8260-E50A503A0C32 Q35549083-DE1E416A-6D13-4A57-9552-A9637616308B

P2860

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

http://www.wikidata.org/entity/Q28383993

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

@ast

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

@en

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

@nl

type

label

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

@ast

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

@en

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

@nl

prefLabel

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

@ast

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

@en

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

@nl

P1433

Q28383993-77F4F93A-15E8-4E28-84A4-A048D2BB662B

P1476

Q28383993-4CF3D212-93D5-4DAE-B533-69AEAF5985D5

P2093

Q28383993-00E79049-CA9E-4FAB-B1E0-B822EE1B3B0E

Q28383993-0A66DBBF-84CD-4C86-913E-8CFE7F33994B

Q28383993-1E074DAF-296C-44AC-ADCE-15661B1F2278

Q28383993-38D1A78F-7A1E-497A-915A-0E47ED9F7CA2

Q28383993-81678A1E-8607-4FF2-8248-16376423FE72

Q28383993-840B8204-69C8-4ABD-8FAF-6A447AAB5072

Q28383993-926045A0-149B-43A5-8E57-9D23E156F3A9

Q28383993-A1150288-91D1-4022-B49F-FF04A069CBF5

Q28383993-A4FDFCD0-D352-49C2-B4A4-4C5D038A4B32

Q28383993-A5C834BC-5824-47DE-9998-9C0E1056163B

P2860

Q28383993-0082969F-930B-4D7D-8CFD-61D6DE9E768C

Q28383993-180E3C45-4DB1-4988-BC06-4CB20FE746B9

Q28383993-22AB3DC7-EE66-45C4-8E06-B3A087029B4E

Q28383993-24C0BD6C-2992-4FD4-85CF-F2D3295EFC49

Q28383993-3CAD54E2-202D-4047-9A3A-3677F4799ED1

Q28383993-489C07A1-FFA5-4697-9276-0F25A52409AB

Q28383993-532408AF-C7B6-43F8-B966-1F92F9E273BB

Q28383993-5541D238-E9E6-46DF-83E8-4AE416009788

Q28383993-5681E405-9B36-420E-B534-BD83DC926310

Q28383993-5D8665A5-9797-4691-8BB2-BF983413E150

P304

Q28383993-8CEC6961-B83C-4D3E-A4D9-674E2C839A73

P31

Q28383993-2EF71318-F599-4768-835A-FCE6B812574B

P3181

Q28383993-10E63977-5CF3-4DD1-90DF-74829DF0C3CB

P356

Q28383993-D6712C9C-24FF-4FE6-84E7-FD0B2B0D5AB9

P407

Q28383993-ED6243C7-577F-45AF-AC42-E5870CB4EDEE

P433

Q28383993-9E940E64-51F6-4A5A-B4A5-2C1727077D45

P478

Q28383993-23C251B6-E71D-42E3-AC21-CB932F891300

P50

Q28383993-A2100AA2-ED4E-49A7-8254-CFF5C1F01CC6

Q28383993-A90F35A6-56E0-4E0D-86A1-50F78E797BD9

Q28383993-FBF7FF97-509A-4AF9-98FD-713602CB67C9

P577

Q28383993-BEBBA818-A199-43E1-B7D4-4EFCA78399A3

P5875

Q28383993-9307BDAE-7818-42A4-BEF8-B32EFB97551B

P698

Q28383993-4A337239-5192-4D86-8A18-32B230621292

P921

Q28383993-6C71488D-DEB6-4533-8A58-966ECAA802FD

P932

Q28383993-AEE4844A-F463-4D88-8E73-73506DB08763

P3181

P356

JCO.2005.03.6772

P1433

Journal of Clinical Oncology

P1476

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

@en

P2093

Andrea Eisen

http://www.w3.org/2001/XMLSchema#string

Barbara L Weber

http://www.w3.org/2001/XMLSchema#string

Beth N Peshkin

http://www.w3.org/2001/XMLSchema#string

Camille Corio

http://www.w3.org/2001/XMLSchema#string

David M Euhus

http://www.w3.org/2001/XMLSchema#string

Debra Dutson

http://www.w3.org/2001/XMLSchema#string

Dianne Finkelstein

http://www.w3.org/2001/XMLSchema#string

Donald A Berry

http://www.w3.org/2001/XMLSchema#string

Edwin S Iversen

http://www.w3.org/2001/XMLSchema#string

Gail Tomlinson

http://www.w3.org/2001/XMLSchema#string

P2860

Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

Population-Calibrated Gene Characterization: Estimating Age at Onset Distributions Associated With Cancer Genes

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

Logistic regression of family data from retrospective study designs.

BayesMendel: an R environment for Mendelian risk prediction

Clinical management of BRCA1- and BRCA2-associated breast cancer.

P304

863-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

160703

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2005.03.6772

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Joellen M Schildkraut

Christopher Amos

Claudine Isaacs

P577

2006-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7291850

http://www.w3.org/2001/XMLSchema#string

P698

16484695

http://www.w3.org/2001/XMLSchema#string

P921

Ameeriga Ütisriigiq

P932

2323978

http://www.w3.org/2001/XMLSchema#string